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Delivery of siRNA using ternary complexes
containing branched cationic peptides: the role
of peptide sequence, branching and targeting†
Laila Kudsiova,a Katharina Welser,‡b Frederick Campbell,§b Atefeh Mohammadi,b
Natalie Dawson,b Lili Cui,a Helen C. Hailes,b M. Jayne Lawrencea and
Alethea B. Tabor*b
Ternary nanocomplexes, composed of bifunctional cationic peptides, lipids and siRNA, as delivery vehicles
for siRNA have been investigated. The study is the first to determine the optimal sequence and architecture
of the bifunctional cationic peptide used for siRNA packaging and delivery using lipopolyplexes. Specifically
three series of cationic peptides of diﬀering sequence, degrees of branching and cell-targeting sequences
were co-formulated with siRNA and vesicles prepared from a 1 : 1 molar ratio of the cationic lipid DOTMA
and the helper lipid, DOPE. The level of siRNA knockdown achieved in the human alveolar cell line,
A549-luc cells, in both reduced serum and in serum supplemented media was evaluated, and the results
correlated to the nanocomplex structure (established using a range of physico-chemical tools, namely
small angle neutron scattering, transmission electron microscopy, dynamic light scattering and zeta
potential measurement); the conformational properties of each component (circular dichroism); the
degree of protection of the siRNA in the lipopolyplex (using gel shift assays) and to the cellular uptake,
localisation and toxicity of the nanocomplexes (confocal microscopy). Although the size, charge,
structure and stability of the various lipopolyplexes were broadly similar, it was clear that lipopolyplexes
formulated from branched peptides containing His-Lys sequences perform best as siRNA delivery agents
in serum, with protection of the siRNA in serum balanced against eﬃcient release of the siRNA into the
cytoplasm of the cell.
Introduction
Small interfering RNA (siRNA) can be used to knock down a
wide range of protein targets in viral and cancer cells, raising
the possibility that siRNA can be used as a therapy for the
treatment of cancers and viral infections. In order for siRNA to
be successfully administered in vivo for therapeutic purposes, it
must be packaged into nanoparticles in such a way that it is not
only protected from enzymatic degradation and aggregation by
serum proteins but also targeted to the cell type of interest. Once
the target cell has been reached, the siRNA-carrying nanoparticle
must then be eﬃciently internalised, generally via endocytosis.1,2
Althoughmany of the strategies that have been used for packaging
and cellular delivery of DNA3 have the potential to be adapted
for the delivery of siRNA, siRNA diﬀers from DNA in several
crucial respects.4 Firstly, the 21 nucleotide base pairs of siRNA
are significantly smaller in size than the plasmid DNA usually
used for gene delivery, so it is likely that siRNA containing
nanoparticle formulations will contain more than one siRNA
molecule. In addition, whereas plasmid DNA can be highly con-
densed by complexation with cationic lipids or polymers to form
lipoplexes or polyplexes, siRNA (21 base pairs) is unlikely to be
significantly condensed, preferring instead to behave as a rigid rod.
Finally, although both nanoparticles carrying siRNA and plasmid
DNA must both escape from the endosome, plasmid DNA has to
reach the nucleus in order for gene expression to occur, whereas
siRNA has the advantage of only having to be released into the
cytoplasm where it will be loaded onto the multi-protein RNA-
inducing silencing complex (RISC) thereby initiating the process
of sequence-specific degradation of the mRNA targets.4
Cationic polymers, which can complex negatively charged
siRNA into nanosized particles, have been successfully used
for siRNA delivery in vitro.1–4 Nanoparticles formulated with
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cationic dendrimers such as poly(amido amine) (PAMAM) have
been particularly effective in delivering siRNA for gene silencing.
However, very few siRNA delivery systems are currently in pre-
clinical studies or in clinical trials.2 One major drawback for
clinical applications of cationic dendrimer-containing formula-
tions is their toxicity. Cationic dendrimers are cytotoxic due
to their interactions with biological membranes as well as
their induced haemolytic and haematological toxicity.5 Nano-
particles formulated from siRNA and cationic peptides (either
linear or branched) may therefore be an attractive alternative
for siRNA delivery, because of their reduced toxicity and their
potential biodegradability.
Two approaches to the design of cationic peptide sequences
for the complexation and delivery of siRNA to cells have been
reported, exploiting either Arg-rich, or mixed His/Lys, sequences
of cationic residues. The first approach was based on the observa-
tion that cell-penetrating peptides (CPP) are frequently Arg-rich
sequences. It is believed that nanoparticles incorporating CPP
sequences can translocate directly into cells through the cell
membrane, or enter cells via endocytosis.6 Indeed non-covalent
nanocomplexes of siRNA with7 (L-Arg)9 or with
8 (L-Arg)8 have been
successfully used to deliver siRNA into cells, with the siRNA
localised at the perinuclear region after release from the complex.
After uptake of these nanocomplexes into the cells via endocytosis,
the CPP may also disrupt the endosomal membrane, allowing
the siRNA to be released into the cytoplasm. Kumar et al. used a
chimaeric peptide, consisting of a 29-residue sequence of the rabies
virus glycoprotein (RVG) linked to a (D-Arg)9 sequence, to bind and
deliver siRNA to neuronal cells in vitro.9 The same complex of
chimaeric peptide and siRNA was also used to successfully deliver
siRNA to macrophages,10 while a CD7-specific single chain anti-
body conjugated to (D-Arg)9 was used to selectively deliver siRNA
to T cells.11 In these formulations, it was believed that as the
unnatural D-Arg residues are not recognised by enzymes or
receptors, these cationic peptides cannot act as CPP and are
resistant to serum proteases in vivo.11
The second approach was based on the hypothesis that nano-
complexes containing His-rich peptide sequences are able to
act as a ‘‘proton sponge’’ and thus to neutralise the acidity of
the interior of the endosome. This is believed to lead to swelling
and rupture of the endosome with subsequent release of the
nanocomplexes into the cytoplasm.12 Mixson and co-workers
studied highly branched peptide carriers, with diﬀerent repeating
sequences of His and Lys residues in the branches, and targeted
with an integrin-binding RGD sequence at the C-terminus, as
reagents for the delivery of siRNA.13 Significantly, the level of gene
knockdown achieved with the best peptide carrier was compar-
able to or better than the ‘gold standards’, Lipofectamine 2000 or
Oligofectamine but without their associated toxicity.13 It was also
found that branched peptide carriers based on sequences such as
(HHHK)4 that resulted in the best level of siRNA delivery, were
significantly diﬀerent from those peptide sequences previously
optimised by this group for successful plasmid DNA delivery.
These siRNA/(HHHK)4 peptide carrier nanocomplexes were also
shown to be eﬀective for systemic delivery in vivo.14 PEG-modified
versions of these nanocomplexes with cRGD targeted ligands
showed good pharmacokinetics and tumor-selective siRNA
delivery in vivo.15,16 Linear, amphipathic histidine-rich peptide
sequences, which also contain Lys, Ala and Leu residues, have
also been reported to be eﬀective for siRNA delivery,17 and
disulfide-linked polymers of Cys-His-Lys peptides18 have been
used to deliver a broad range of nucleic acids, including siRNA.19
The gene delivery properties of ternary nanocomplexes,
known as lipopolyplexes, composed of lipid, peptide and DNA,
have recently been investigated, using: a bifunctional peptide
with a (Lys)16 domain to bind and condense DNA and a cyclic
peptide targeting domain that partially protrudes from the nano-
complex and mediates cell-specific receptor-mediated endocytosis
of the vector;20 and a 1 :1 mixture of a cationic lipid, structurally
related to N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium
chloride (DOTMA), and the neutral lipid, dioleylphosphatidy-
lethanolamine (DOPE) (which can enhance liposome fusion with
the endosomal membrane, leading to endosomal escape21). This
vector has been optimised for a number of applications, including
the development of a peptide targeting sequence for gene
delivery to respiratory cells.22 Shielding lipids containing short
ethylene glycol (EG) sequences,23–25 and peptides that are cleaved
within the endosome25 to give vectors that are stable in the
systemic circulation but disassemble once internalized,25,26 have
been incorporated. The effect of lipid chain geometry on the
structure and transfection properties of lipopolyplexes and
lipoplexes (binary complexes of lipid and DNA) has also been
investigated.27,28 Most recently, the effect of cationic residue
sequence and branching on the level of plasmid DNA deliver
achieved with lipopolyplexes has been studied, with branched
Arg-rich peptides and linear Lys-rich peptides beingmost effective.29
In this work, the eﬀects of varying the sequence of cationic
residues and the degree of branching on the packaging and
delivery of siRNA in DOTMA:DOPE:peptide:siRNA lipopolyplexes
(LPRs) have been studied. In light of the various studies on
polyplex delivery of siRNA reported by other groups, we have for
the first time carried out a detailed comparison of whether Lys,
His, L-Arg, D-Arg or mixed His/Lys sequences would be most
eﬀective in mediating siRNA delivery, in both peptide:siRNA
polyplexes (PR) and LPR formulations. We have also investi-
gated the eﬀect of peptide sequence and structure on the
overall structure, siRNA protection, and cytoplasmic release of
the nanocomplex, and are able to relate this to the eﬀectiveness
of the LPRs as siRNA delivery vehicles.
Results
Peptide design
A comprehensive set of linear (B0), singly (B1) and doubly-
branched polycationic peptides (B2) has been studied to explore
the eﬀect of both cationic sequence and peptide structure on
the complexation of siRNA and the gene silencing eﬃciency of
LPRs. To test the LPRs in a human alveolar cell line, the peptide
sequences included a targeting sequence, CYGLPHKFC (sequence
[Y]) which was selected by phage display to bind human airway
epithelial cells and mediate good DNA transfection eﬃciency.22
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The targeting [Y] and polycationic sequences are linked by either a
non-cleavable spacer sequence (GAGA (L2)) or a cleavable sequence
(RVRRGA (L1)). L1 is recognised by the endosomal enzyme furin,
and peptides containing this sequence have been previously
demonstrated to enhance DNA transfection by LPD complexes.25,26
Three groups of peptides were synthesised for formulation
and testing. In Group 1 we aimed to compare the eﬀects of Lys,
Arg, D-Arg and His residues in peptides of the same length and
degree of branching (Fig. 1). In order to determine whether or
not the targeting sequence plays a major role in cellular uptake
a control, sK6B1-L1-[Y], with a scrambled version of the [Y]
sequence, was prepared. The Group 2 peptides are designed to
compare the eﬀects of linear, singly and doubly branched
peptides on LPR knockdown, and a second control peptide,
K12, (devoid of a targeting sequence) has also been included to
investigate the role of the targeting sequence. Four peptides
(Group 3) based on the alternating HK sequences recently
reported by Mixson and co-workers,13 were also studied. In this
paper, repeating HHHK sequences in 4-branched and 8-branched
peptides were found to be particularly eﬀective in siRNA delivery,
and therefore the singly-branched peptides (H3K)4B1-L1-[Y]
and (KH3)4B1-L1-[Y] were prepared. In contrast, Mixson and
co-workers reported that HHK sequences were less eﬀective for
siRNA delivery but gave better pDNA transfection, and the peptide
(HHK)4B1-L1-[Y] was therefore also studied. As a further
comparison, a fourth peptide based on a repeating HHHHK
sequence, (H4K)3B1-L1-[Y] was synthesised. All LPRs were pre-
pared using vesicles comprising of a 1 : 1 molar ratio of cationic
lipid, DOTMA, and neutral helper lipid, DOPE, (Lipofectins).
For the purposes of comparison the biophysical and transfection
properties of PRs, prepared by complexing the various peptides
with siRNA, were investigated.
In vitro knockdown experiments
Knockdown experiments with LPRs, made using the various
peptides at charge ratios of 0.5 : 6 : 1 or 0.5 : 12 : 1 and prepared
either in water and diluted 1 in 4 in OptiMEM (water/OptiMEM)
or OptiMEM diluted 1 in 4 with serum-containing growth
medium (OptiMEM/Medium), were performed in a stably trans-
fected A549-Luc cell line (Fig. 2). A comparable level of knock-
down to the (water/OptiMEM) experiment was achieved when
LPRs were prepared fully in OptiMem, and little knockdown
was achieved when LPRs were prepared in water and diluted
1 in 4 with serum-containing growth medium (water/Medium)
(Fig. S1, ESI†). For comparison, the knockdowns obtained with
PRs when formulated fully in OptiMEM are given in Fig. S2,
ESI.†
High levels of knockdown were achieved in the water/OptiMEM
preparation (Fig. 2a–c), and when LPRs were prepared fully in
OptiMEM (Fig. S1a–c, ESI†), for the majority of peptide sequences.
Fig. 1 Structures of Group 1, Group 2 and Group 3 peptides.
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Poor or negligible knockdown was obtained with the PRs pre-
pared under the same conditions, clearly showing the benefit of
formulating LPRs rather than PRs.
The greatest level of knockdown, in fact greater than that
exhibited by the positive control, L2K, was observed with LPRs
prepared using Group 3 peptides (Fig. 2c). These Group 3
peptides included the HHHK sequences identified by Mixson
and co-workers13 as highly eﬀective for siRNA delivery (peptides
(KH3)4B1-L1-[Y] and (H3K)4B1-L1-[Y]) as well as two other alter-
nating HK sequence peptides. Furthermore, with the exception
of doubly branched K6B2-L1-[Y] peptide (and K6B1-L1-[Y] and
K12B0-L1-Y when prepared fully in OptiMEM) increasing the
charge ratio of the peptide in the LPR from 0.5 : 6 : 1 to 0.5 : 12 : 1
in the LPR formulations prepared in OptiMEM or water/OptiMEM
did not significantly influence knockdown eﬃciency. This result is
in contrast to LPD formulations, where DNA transfection increased
upon increasing charge ratio of the peptide from 0.5 : 6 : 1 to
0.5 : 12 : 1.29
LPRs formulated in water/OptiMEM using the Group 1 pep-
tides did not show major diﬀerences in knockdown eﬃciency
(Fig. 2a). Furthermore, no diﬀerence in knockdown eﬃciency was
seen when comparing LPRs prepared using peptides containing
the enzymatically cleavable RVRRGA (L1) linker to those posses-
sing the non-cleavable GAGA (L2) linker. It is also notable that the
control peptide, sK6B1-L1-[Y], with a scrambled version of the [Y]
sequence, gave similarly good knockdown results, suggesting
that under these conditions receptor binding and uptake of the
LPR complexes is also not the crucial step for knockdown.
Finally, whilst the His-containing peptides H6B1-L1-[Y] and
H6B1-L2-[Y] should have a lower charge at pH 7 when compared
to the other sequences, this also does not have any influence on
knockdown eﬃciencies.
LPRs containing the singly branched peptides in Group 2,
K4B1-L1-[Y] and K6B1-L1-[Y], were slightly more eﬀective knock-
down agents than the LPRs with the linear K6B0-L1-[Y] in water/
OptiMEM. However, the extent of peptide branching did not
play a significant role in knockdown as further branching of
the peptide (K6B2-L1-[Y]) did not improve knockdown eﬃciency
(Fig. 2b). A further control peptide, K16, lacking any targeting
sequence, also gave equally good knockdown results.
The eﬀect of the presence of serum on the knockdown
eﬃciency of the LPRs was also examined. It is of particular
note that LPRs prepared in water and diluted in media containing
10% FBS showed very poor knockdown eﬃciencies, as did indeed
the positive control when prepared under the same conditions
(Fig. S1, ESI†).
This poor knockdown is attributed to the presence of
negatively charged serum proteins, present in the growth
media, neutralizing the cationic charge of the LPRs, most
probably leading to their aggregation and thereby reducing
their interaction with the negatively charged cell. In contrast,
when the LPRs were prepared in OptiMEM and diluted in
growth media (Fig. 2d–f), the knockdown activity of a number
of the complexes, including those containing L2K was, at least
partially, maintained.
The lower knockdown eﬃciencies seen in the presence of
serum revealed diﬀerences in the extent of knockdown achieved
using the various peptides, making certain interesting trends
clear. Firstly, as with the LPRs prepared in water and then
OptiMEM, and indeed fully in OptiMEM, no diﬀerence was seen
in increasing the charge ratio of the peptide in the LPR from
0.5 : 6 : 1 to 0.5 : 12 : 1. Secondly, in the presence of serum the
greatest knockdown was achieved using peptides containing
histidine – in particular the results obtained using the Group 3
Fig. 2 Percentage knockdown (calculated as % using luminescence produced by each complex when formulated with negative control siRNA and
normalised according to the protein content) of LPRs at 0.5 : 6 : 1 (grey bars) or 0.5 : 12 : 1 (black bars) charge ratios, prepared using (a and d) Group 1,
(b and e) Group 2, and (c and f) Group 3 peptides. LPRs were prepared either in (a–c) water then diluted in OptiMEM (water content = 12.5% v/v); or in
(d–f) in OptiMEM then diluted in serum-containing growth media (OptiMEM content = 12.5% v/v). siRNA alone and L2K : siRNA at 5 : 1 weight ratio were
used as controls. siRNA concentration was 50 nM per well.
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peptides which achieved knockdowns of up to B70%, with
LPRs containing (KH3)4B1-L1-[Y] and (H3K)4B1-L1-[Y] being
most effective. Similarly, within the Group 1 peptides (Fig. 2d),
the complexes prepared using the His-containing peptides,
H6B1-L1-[Y] and H6B1-L2-[Y] produced the greatest knockdown
while LPRs prepared using K6B1-L1-[Y] and R6B1-L1-[Y] showed
no activity whatsoever.
Again, with the exception of LPRs containing the peptides,
H6B1-L1-[Y] and H6B1-L2-[Y], LPRs prepared (OptiMEM/
Medium) using peptides containing the non-cleavable GAGA
(L2) linker showed significantly better activity in the presence
of serum than those containing the cationic Arg-rich RVRRGA
(L1) linker. LPRs containing dR6B1-L1-[Y] were more eﬀective
than those containing R6B1-L1-[Y] (Fig. 2d). In addition, as can
be seen from a consideration of the results obtained using the
Group 2 peptides (Fig. 2e), increasing the degree of branching
and number of cationic peptide residues in the Lys and Arg was
detrimental to knockdown eﬃciency for LPRs. For example, the
best knockdown was produced by LPRs containing the linear
peptide, K6B0-L1-[Y], followed by the Lys containing singly
branched peptide K4B1-L1-[Y], next K6B1-L1-[Y] and finally the
doubly branched K6B2-L1-[Y]. Finally, complexes prepared
using the linear Lys containing peptide, K12B0-L1-[Y], were less
eﬀective than those using K6B0-L1-[Y], or a K12 peptide devoid
of targeting or linker sequences.
The toxicity exerted by the LPRs was measured indirectly
using the protein assay (Fig. S3, ESI†). Most of the LPRs tested,
regardless of their method of preparation, showed over 80%
cell viability compared to untreated controls. In contrast
however, the L2K containing lipoplexes exerted the lowest cell
viability atB70%. Interestingly, LPRs prepared in the presence
of serum-containing media showed higher viability than those
prepared fully in OptiMEM or water/OptiMEM.
Dynamic light scattering and zeta potential
The apparent hydrodynamic size and zeta potential of the LPRs
and PRs are shown in the ESI† (Fig. S4 and S5, respectively).
The LPRs were small, being typically in the size range 45–75 nm
and were positively charged with zeta potentials of between
12–50 mV, with the majority of LPRs exhibiting a zeta potential
of greater than 30 mV. No correlation was observed between
LPR size, zeta potential and the peptide ratio and structure of
the peptide used to prepare the LPR, although there was a clear
tendency for the LPRs containing His or His-rich peptides to
exhibit lower zeta potentials.
In contrast, the apparent hydrodynamic diameters of the
PRs were much larger at up to 1500 nm and more polydisperse
suggesting the presence of much more highly aggregated
particles. Although the zeta potentials of the PRs were positive,
typically in the range 5–38 mV (with the exception of PRs
containing (H4K)3B1-L1-[Y] which were negative, probably due
to the lower charge on the peptide at neutral pH) they were
noticeably lower than the corresponding LPRs. This suggests
that the cationic lipid plays a significant role in the structure of
the complexes both in terms of complex size and charge.
Transmission electron microscopy
In agreement with dynamic light scattering measurements,
transmission electron microscopy (TEM) imaging of selected
LPR and PR formulations showed that the LPRs were small,
homogeneous electron dense, spherical particles with no inter-
nal structure visible (Fig. 3a–e) while the PRs were much more
heterogeneous, demonstrating extensive aggregation (Fig. S6 ESI†).
By way of comparison, LR complexes prepared from DOTMA:
DOPE:siRNA at 0.5 : 1 charge ratio showed particles containing a
lamellar structure (indicated by the arrow in Fig. 3f) typically seen
Fig. 3 Transmission electron microscopy of LPRs prepared using DOTMA:DOPE with the peptides (a) K6B1-L1-[Y], (b) R6B1-L1-[Y], (c) H6B1-L1-[Y],
(d) K12B0-L1-[Y] and (e) K6B2-L1-[Y] at a 0.5 : 6 : 1 LPR charge ratio and (f) DOTMA:DOPE:siRNA LR complexes at a 0.5 : 1 charge ratio. The siRNA
concentration in all samples was 0.05 mg mL1. Size bar represents 200 nm on original images and 50 nm on inserts.
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in DNA lipoplexes.26 This lamellar structure was not observed in
any of the LPR formulations, suggesting that the structure of LPRs
is indeed very different from that of binary complexes composed of
either PR or LR components alone.
Gel retardation assays and PicoGreen fluorescence studies in
the absence of serum
The gel electrophoresis studies indicated that the peptides,
regardless of whether formulated as a LPR or PR, complexed
siRNA to a significant degree at both of the charges ratios
studied (Fig. 4, Lane 1). The only exceptions were the complexes
containing K12B0-L1-[Y], R12B0-L1-[Y] and the Group 3 peptides
(HHK)4B1-L1-[Y], (KH3)4B1-L1-[Y] and (H3K)4B1-L1-[Y], where
the siRNA was more completely complexed at the higher
peptide charge ratio of 0.5 : 12 : 1 for LPRs and 12 : 1 for PRs.
In addition, incomplete siRNA complexation was observed with
the histidine containing peptides, H6B1-L1-[Y],H6B1-L2-[Y] and
(H4K)3B1-L1-[Y] at both peptide charge ratios studied. Treat-
ment of the LPRs and PRs with pAsp resulted in the expected
dissociation of siRNA from the complexes (Fig. 4, Lane 2).
Significantly LPRs and PRs treated with RNAse A followed by
RNAse inhibitor and pAsp (Fig. 4, Lane 3) in order to assess the
stability of the complexed siRNA to enzymatic degradation,
suggested that all the complexes significantly protected siRNA
from RNAse (Fig. 4, Lane 3), while naked siRNA was completely
degraded by RNAse A under the same circumstances (Fig. 4,
Lane B).
PicoGreen fluorescence studies were performed to further
study the eﬀectiveness of the packaging of siRNA within the
LPR complexes (Fig. 5). Accessibility of PicoGreen to siRNA
results in a reduction of its fluorescence intensity. In agreement
with the gel retardation studies, a drastic reduction in fluores-
cence intensity was seen upon increasing the peptide content in
the LPR complexes, reaching a plateau (suggesting that maximum
complexation had been reached for that complex) at LPR
charge ratios of between 0.5 : 2 : 1 and 0.5 : 18 : 1, the exact ratio
depending upon the peptide used. For most complexes the
plateau (or maximum complexation) was reached at LPR charge
Fig. 4 Gel electrophoresis of LPR and PR complexes containing (a) Group 1, (b) Group 2 and (c) Group 3 peptides. LPR complexes were prepared with a
charge ratio of lipid : peptide : siRNA of 0.5 : 6 : 1 and 0.5 : 12 : 1 while PR complexes were prepared with a charge ratio of peptide : siRNA of 6 : 1 and 12 : 1.
The eﬀect of the peptide component on siRNA complexation, protection from degradation by RNAse A and on siRNA release is labelled by Lanes 1, 2,
and 3 respectively. Lane 1: untreated complexes. Lane 2: complexes treated with RNAse A followed by pAsp. Lane 3: complexes treated with pAsp only.
Lane A: siRNA control. Lane B: siRNA treated with RNAse A.
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ratios of 0.5 : 4 : 1, the exception being the complexes prepared
using the Group 3 peptides, and in particular (H3K)4B1-L1-[Y],
where a plateau was only reached at LPR charge ratios of
0.5 : 12 : 1. In addition, the extent of complexation, indicated
by the fluorescence intensity of the plateau region, was strongly
influenced by the nature of the peptide used to prepare the
complex. For example, only a small reduction in fluorescence
intensity of 10 and 40% of the intensity of free siRNA was
observed in LPRs formulated with the His-only containing
peptides H6B1-L1-[Y] and H6B1-L2-[Y], respectively (Fig. 5a).
This contrasted with a B70% reduction in fluorescence seen
with complexes containing Group 3 peptides comprising both
His and Lys residues. The maximum reduction in fluorescence
intensity of 95% was achieved with complexes prepared using
the Arg and Lys rich peptides, namely R6B1-L1-[Y], R6B1-L2-[Y],
dR6B1-L1-[Y] and K12B0-L1-[Y] (Fig. 5a and c).
Gel retardation assays in the presence of serum
Further gel electrophoresis studies were performed (Fig. 6) to
study the complexation and stability under various conditions
of LPRs prepared using 6 selected peptides, namely K6B1-L1-[Y],
R6B1-L1-[Y], H6B1-L1-[Y], K12B0-L1-[Y], K6B2-L1-[Y] and
(H3K)4B1-L1-[Y]. These peptides were selected for further study
as they represented a cross selection of the peptides studied,
with some facilitating a good degree of knockdown in the presence
of serum while others appeared to be ineﬀective. The LPRs were
therefore prepared in a range of aqueous solvents, namely fully in
water, or 12.5% v/v water diluted in 10% FBS solution, OptiMEM or
serum-containing growth medium or alternately fully prepared in
OptiMEM or fully in serum-containing media. It should be noted
that the degradation of naked siRNA observed when dissolved in
10% FBS in water was undoubtedly due to the RNAses naturally
present in serum.30 In contrast no degradation was observed when
the siRNA was dissolved in water before addition to serum-
containing media (which also contains 10% FBS) or (FBS-free)
OptiMEM (Fig. 6, Lanes C and D). Furthermore, partial degra-
dation of the siRNA was observed when it was prepared directly
in serum-containing media. These results suggest that the action
Fig. 5 Picogreen fluorescence binding assay showing siRNA packaging
within LPR complexes using (a) Group 1, (b) Group 2 and (c) Group 3
peptides. LPR complexes were prepared with constant charge ratios of
lipid and siRNA (0.5 : 1) and varying peptide charge ratios (x = 1–18).
Relative fluorescence units (RFU) of the LPR complexes were calculated
as percentage fluorescence from free siRNA.
Fig. 6 Gel electrophoresis of LPR complexes containing peptides K6B1-L1-[Y], R6B1-L1-[Y], H6B1-L1-[Y], K12B0-L1-[Y], K6B2-L1-[Y] and (H3K)4B1-L1-[Y] at
a 0.5 : 6 : 1 charge ratio. Free siRNA and L2K : siRNA at 5 : 1 weight ratio were used as controls. Samples were prepared in (A) fully in water, (B) 12.5% v/v water
diluted in 10% FBS, (C) 12.5% v/v water diluted in OptiMEM, (D) 12.5% v/v water diluted in media, (E) fully in OptiMEM and (F) fully in media and were incubated
at 37 1C for 60 minutes prior to the gel electrophoresis experiment being performed.
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of RNAses present in serum might to some extent be inhibited by
components present in media. It is not clear what component in
the growth medium exerts this eﬀect especially since RNAse free
media was not used in the study. When serum containing media
(no siRNA or LPR present) was examined by electrophoresis a new
high molecular weight band was seen on the gel, which was
thought to be due to fluorescence produced by the interaction of
serum protein with GelRed nucleic acid stain. The presence of this
band is not thought to interfere with the bands observed in the
presence of siRNA or LPR.
For the purposes of comparison, the corresponding results
obtained using LRs prepared using L2K are shown. Although
L2K is shown to complex siRNA eﬃciently in water (Fig. 6, Lane A),
some siRNA release (and possible degradation) is detected in the
other conditions tested. Interestingly, LPRs were shown to complex
and protect siRNA to diﬀerent extents in the diﬀerent conditions.
When comparing the complexation achieved using the Lys, Arg
and His only-containing peptides – K6B1-L1-[Y], R6B1-L1-[Y] and
H6B1-L1-[Y] – it is clear that the LPR containing R6B1-L1-[Y]
exhibited the highest degree of siRNA complexation when pre-
pared in water and in OptiMEMwith all the electrolytes it contains
(Fig. 6, Lanes A, C and E) but only in the absence of serum (Fig. 6,
Lanes B, D and F). In the case of K6B1-L1-[Y], although well
complexed in water, some dissociation of siRNA was observed in
OptiMEM (Fig. 6, Lanes C, E) as well as in the serum containing
aqueous solvents. As for H6B1-L1-[Y], inefficient complexation was
evident under all the conditions tested. Furthermore, some siRNA
degradation was evident in the presence of 10% FBS as evidenced
by the fainter siRNA (lower) band seen in Lane B. The Group 3
peptide, (H3K)4B1-L1-[Y], behaved in a very similar manner to
H6B1-L1-[Y].
When comparing the eﬀect of peptide branching, it was clear
that although the linear peptide, K12B0-L1-[Y] behaved in a very
similar way to its singly branched counterpart, K6B1-L1-[Y], the
double branched K6B2-L1-[Y] exhibited a significantly greater
stability towards siRNA dissociation in the presence of both
OptiMEM and serum, demonstrating an even higher degree of
complexation than L2K. The reduced knockdown eﬃciency of
the doubly branched peptide, K6B2-L1-[Y], could therefore be a
consequence of excessive binding that the peptide exerts on
siRNA, possibly preventing the dissociation of siRNA within
the cell.
Circular dichroism studies
Circular dichroism (CD) spectra of siRNA, 6 selected peptides
(namely, H6B1-L1-[Y], K6B1-L1-[Y], R6B1-L1-[Y], K12B0-L1-[Y],
K6B2-L1-[Y] and (H3K)4B1-L1-[Y]) and their respective PR, LPR
and lipid:siRNA (LR) complexes at diﬀerent charge ratios using
DOTMA:DOPE vesicles were measured (Fig. 7 and Fig. S7, ESI†).
It should be noted that despite the relatively large size measured
for some of the complexes, particularly the PRs, all preparations
appeared clear, and showed very little evidence of light scattering,
as assessed by simultaneousmeasurement of the UV spectroscopy
of the samples (data not shown).
The CD spectra of individual LPR components were measured
initially. Peptides alone dissolved in D2O exhibited a positive peak
atB220 nm and a large negative signal atB200 nm, indicative of
the peptides adopting, in solution a polyproline II (PII) conforma-
tion characterized by a left-handed helical turn31 (Fig. 7a and b).
Normalising the CD spectra according to the number of amide
residues per mole of peptide (Fig. 7b) revealed that K6B1-L1-[Y]
exhibits the strongest PII conformation, while the rest of the
peptides exist in equilibrium between PII and disordered state.
siRNA alone was seen to adopt the characteristic A-form con-
formation with high positive and negative peaks at 260 nm and
210 nm respectively (Fig. S7, ESI†). Any change in the intensity
of the peaks at 260 nm and 210 nm respectively, indicates
changes in base stacking32 and/or the siRNA backbone structure,33
respectively. DOTMA:DOPE vesicles in D2O did not exhibit a CD
spectrum at the range of concentrations tested.
To understand the nature of the ternary complexes, the binary
complexes were first studied. Subsequently, the CD spectra of LRs
were then measured to determine the siRNA conformation when
complexed with DOTMA:DOPE at LR charge ratios of 0.5 : 1–4 : 1,
the lowest lipid ratio being similar to that used in LPR complexes.
Spectra of LRs showed a reduction in the intensity of the positive
peak at B260 nm and a deepening of the trough at 210 nm at
all ratios tested when compared to the spectrum of free siRNA
(Fig. S7e ESI†). By subtracting the CD spectrum of free siRNA
from that of the LR complexes, (and since DOTMA:DOPE itself
does not exhibit a CD spectrum), any deviation in the shape of
the subtracted CD spectra from baseline indicates a change in
siRNA conformation (Fig. 7c).
The interaction of DOTMA:DOPE with siRNA is therefore
thought to results in a change in base stacking of siRNA, as well
as a change of siRNA backbone conformation. Interestingly, the
reduction in band intensity at 260 nm in particular was not
progressive upon increasing the lipid content, as previously
observed in the case of lipid:DNA complexes,29 suggesting that
a change in siRNA conformation was achieved at low (0.5 : 1)
lipid : siRNA charge ratios, and the addition of further lipid did
not cause any further conformational change in siRNA.
When examining the formation of PRs, the addition of
peptide to siRNA did not cause significant changes in siRNA
conformation, since the intensity of the positive band at
260 nm was preserved (Fig. S7b–f, ESI†). When studying the
ternary, LPR complexes, the band at 260 nm was similarly
preserved, despite containing the same lipid content as that
of an LR at 0.5 : 1 charge ratio, suggesting that the binding of
the cationic peptides with siRNA takes precedence over the
interaction of the lipid with siRNA.
In order to determine any changes in peptide conformation
within a PR or an LPR complex, the CD spectrum of free siRNA
was subtracted from those obtained for PR and LPR complexes
and compared to the spectrum of their respective peptides in
solution (Fig. 7d–i). Any difference suggests a conformational
change in either the siRNA or the peptide in the complex.
However, since the peptides do not exhibit any CD at wave-
lengths greater than 230 nm, and very little change in the
conformation of siRNA is observed in that region in both PR
and LPR complexes, any changes in spectra below 230 nm were
attributed to changes in peptide rather than siRNA conformation.
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Differences in peptide conformation are shown through a
reduction in the intensity of the peaks and troughs at 220 nm
and 200 nm respectively (Fig. 7d–i). Interestingly the most
prominent differences are observed in peptides H6B1-L1-[Y],
K6B1-L1-[Y] and (H3K)4B1-L1-[Y] (Fig. 7d, e and i), which have
also shown the least siRNA binding capacity in gel electrophoresis
and PicoGreen fluorescence studies. On the other hand, peptides
R6B1-L1-[Y] and K6B2-L1-[Y], which were shown to bind siRNA
the strongest, had preserved band intensities at 200 nm. It is
unclear, however, whether the preserved conformation of pep-
tides R6B1-L1-[Y] and K6B2-L1-[Y] in the complexes enhances
their ability to complex siRNA more effectively, thereby hindering
siRNA dissociation within the cell. In this context it is worth
noting that gel electrophoresis (Fig. 6) indicates that the dissocia-
tion of siRNA in the presence of electrolytes contained within
OptiMEM and serum-containing media was lowest in these two
peptides.
Small angle neutron scattering
The small angle neutron scattering (SANS) profiles were recorded
for DOTMA :DOPE vesicles (1 : 1 molar ratio, at a final DOTMA
concentration of 1 mg mL1 in D2O) and for LPR complexes
formed from selected peptides at a charge ratio 0.5 : 6 : 1, namely
(b) K12, (c) (H3K)4B1-L1-[Y] and (d) H6B1-L1-[Y] (Fig. 8). The
corresponding data for LPRs containing peptides R6B1-L1-[Y],
K12B0-L1-[Y], K6B2-L1-[Y], K6B1-L1-[Y] and K6B0-L1-[Y] are given
in Fig. S8, ESI.† Note that SANS experiments were not performed
on the PRs due to their large size and high polydispersity coupled
with the lack of any discernible internal structure in the
complexes from TEM.
The variation in the intensity of the SANS as a function of
Q for cationic vesicles prepared using a 1 : 1 molar ratio of
DOTMA and DOPE at a DOTMA concentration of 1 mg mL1 in
D2O (Fig. 8a) is in agreement with that obtained in our previous
studies.29 Due to the relatively large average size of the cationic
vesicles, the SANS data was modelled assuming either single
flat sheets (i.e., unilamellar vesicles) or a combination of sheets
and stacks (i.e., multilamellar vesicles). The modelling suggested
the presence of vesicles that were predominantly unilamellar in
nature, and that only a few multilamellar vesicles were present
with about 3–4% of the lipid being in the form of multilamellar
vesicles. This result correlates well with the relatively small
Fig. 7 CD spectra of the peptides H6B1-L1-[Y], K6B1-L1-[Y], R6B1-L1-[Y], K12B0-L1-[Y], K6B2-L1-[Y] and (H3K)4B1-L1-[Y] (a) at concentrations
equivalent to those used in PR and LPR complexes and (b) normalised according to amide residues per peptide, (c) CD spectra of DOTMA:DOPE
vesicles alone (black line) compared to LR complexes at various charge ratios minus the spectrum of siRNA at 4 mM, (d-i) CD spectra of the above
peptides alone (black line) at concentrations equivalent to those used in PR and LPR complexes, compared to the spectra of PR (light grey) and LPR
complexes (dark grey) at 6 : 1 or 0.5 : 6 : 1 charge ratios respectively, from which the spectrum of free siRNA at 4 mM is subtracted to show diﬀerences in
siRNA or peptide conformation.
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vesicle size measured by dynamic light scattering, which was
indicative of the presence of very few multilamellar vesicles. The
thickness and repeat distance (of D spacing) of 41.5 Å and 65 Å
reported in this study agree well with values of 44.7 Å and 65 Å,
previously reported for DOTMA :DOPE vesicles (1 : 1 molar
ratio)27 and with 39 Å and 65 Å reported for related DOTAP :
DOPE vesicles (1 : 1 mola ratio).34,35 Furthermore, the use of a Rs
of 250 Å to fit the data agrees well with that used in previous
analysis of similar systems.27–29 Significantly, the DOTMA:DOPE
vesicles examined using SANS were those used to prepare the
LPR complexes.
SANS data for LPR complexes are shown in Fig. 8b–d and in
Fig. S8, ESI.† With the exception of LPRs prepared using two
peptides, namely H6B1-L1-[Y] and K6B0-L1-[Y] the scattering
patterns recorded for the others LPRs are both qualitatively
very similar to one another and to their parent DOTMA:DOPE
vesicles. These scattering patterns suggest that the LPRs contain
one or, in a small number of instances, more lipid bilayers.
Furthermore, it was possible to fit the data obtained from all
other LPRs, with the exception of those containing K6B2-L1-[Y]
and K6B1-L1-[Y] using the same parameters as those used to fit
the DOTMA:DOPE vesicles, suggesting that the bilayer present
in the LPRs is by and large the same as in the vesicles. In order
to fit the SANS data obtained for the LPRs containing peptides,
K6B2-L1-[Y] and K6B1-L1-[Y] with comparable parameters to
those obtained for the vesicle bilayers, it was necessary to use
a higher Rs of 380 and 520 Å respectively, suggesting that the
lipid bilayer in these LPRs is in a more rigid state. Unfortu-
nately, due to the limited data sets available, it is not possible to
unambiguously state that the bilayer in these LPRs is more rigid
as, for example, it is also possible to these data sets using different
parameters, such as a bilayer of different thickness. However, from
a knowledge of the physico-chemical properties of the systems
under consideration and the known rigidity of siRNA, it would be
reasonable to assume that it is most likely that the rigidity of the
lipid bilayer was increased.
The fact that it was possible to fit the data obtained from the
LPRs using the same parameters as for the parent vesicles was in
line with similar observations made on LPDs prepared using the
same peptides29 and from cationic lipids containing unsaturated
C14 chains.27 In these LPDs it was assumed that the peptide and
DNA complexed with each other and comprised the core of the
lipid bilayer. There is no evidence from the SANS of the formation
of multilayer structures produced from the interaction of cationic
vesicles and siRNA. Furthermore, from inspection of the TEM data
there is no evidence of the large, unstructured aggregates common
for PDs. Hence, while it is not possible to unambiguously state
if all the vesicles contain peptide/siRNA complexes, there is no
evidence to suggest the presence of many, if any, empty vesicles.
Attempts to model the scattering patterns obtained from
H6B1-L1-[Y] and K6B0-L1-[Y] were unsuccessful as it appears
that the preparation consists of mixtures of more than one type
of aggregate. Unfortunately, there was insuﬃcient experimental
data to unambiguously determine the nature of the mixed
aggregates. Indeed close inspection of the TEM data (Fig. 3c,
LPRs prepared using H6B1-L1-[Y]) suggested the presence of
only one type of aggregate. This observation was unexpected
and is currently under investigation.
Fig. 8 Small angle neutron scattering data (dots) at 298 K and the best fit to the data (solid line) obtained using the mixed sheet and stack model for (a)
cationic vesicles prepared from a 1 : 1 molar ratio of DOTMA:DOPE diluted to give the same DOTMA concentration as is present in the LPRs and LPRs
containing (b) K12, (c) (H3K)4B1-L1-[Y] and (d) H6B1-L1-[Y] at a 0.5 : 6 : 1 charge ratio.
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In order to establish whether there was any internal structure
inside the complexes, LPRs were prepared in 8.2 vol% D2O in
H2O. This dispersion medium was specifically selected because
the lipid was contrast matched to the medium and so therefore
‘‘invisible’’ to neutrons, and in this way it should be possible to
determine both the size of any DNA and peptide ‘‘core’’ and to
establish whether the peptide/DNA in the core possessed any
regular structure. However, the concentration of the LPR complex
used in the present study was too low to enable determination of
either the size or the presence of any internal structure.
Confocal fluorescence microscopy
In order to assess the cellular uptake of the LPRs, confocal
fluorescence microscopy studies were performed on A549-Luc
cells transfected with LPRs formulated using six peptides, namely
K6B1-L1-[Y], R6B1-L1-[Y], H6B1-L1-[Y], K12B0-L1-[Y], K6B2-L1-[Y]
and (H3K)4B1-L1-[Y]. LPRs were prepared using Rhodamine-
siRNA (red) and BODIPY-lipid (green) and formulated in water
then diluted with OptiMEM, and incubated with the cells for
4 hours. No significant diﬀerences in fluorescence distribution
(Fig. 9a–f) were observed. In all the samples, the green fluores-
cence due to the lipid appears very punctate, suggesting it
is incorporated within endosomal compartments. Although
co-localisation of (green) lipid with (red) siRNA (seen as yellow)
is seen in some cells in a number of the images, red siRNA is
observed in the majority of cells, suggesting that the siRNA has
predominantly dissociated from the lipid and possibly escaped
from the endosomal compartments. Indeed it is of note that
there is very little nuclear localisation of siRNA or lipid.
Furthermore, two peptides K6B2-L1-[Y] and (H3K)4B1-L1-[Y]
were selected for detailed study as LPRs containing K6B2-L1-[Y]
and (H3K)4B1-L1-[Y] exhibited very low and high knockdown
activities, respectively. The LPRs were prepared either in water
and diluted 1 in 4 in OptiMEM (Fig. 9e–h) or fully in OptiMEM
(Fig. S9, ESI†). These showed no major differences in the
distribution of either lipid (labelled green) or siRNA (labelled
red) after 4 and 24 hours of incubation.
LPRs containing the peptides K6B2-L1-[Y] and (H3K)4B1-L1-[Y]
were also observed after 24 hours of incubation with the cells
(Fig. 9g and h). Interestingly, although the level of lipid due to
green fluoresence was similar in both cases, less siRNA was
detected within the cells in the case of K6B2-L1-[Y] than in the
case of (H3K)4B1-L1-[Y], which could account for the diﬀerence
in knockdown eﬃciency (separate green and red channel figures
are shown in Fig. S10, ESI†). More red fluorescence due to siRNA
was also observed in LPRs prepared using (H3K)4B1-L1-[Y] when
prepared fully in OptiMEM (Fig. S9c and d, ESI†).
In order to determine the eﬀectiveness of release of siRNA
from the two peptides selected for further study, LPR complexes
were formulated using unlabelled lipids, either FITC-K6B2-L1-[Y]
or FITC-(H3K)4B1-L1-[Y] (labelled green), and siRNA (labelled red).
The LPRs were prepared both in water and diluted in OptiMEM,
or fully in OptiMEM. Again, after 24 hours of incubation, a
clear diﬀerence between the amount of siRNA released from
the complex with the two peptides could be detected (Fig. 10).
Fig. 9 Confocal microscopy of A549-luc cells transfected with LPR
complexes prepared in 12.5% water then diluted in OptiMEM containing
peptides (a) K6B1-L1-[Y], (b) R6B1-L1-[Y], (c) H6B1-L1-[Y], (d) K12B0-L1-[Y],
(e) K6B2-L1-[Y] and (f) (H3K)4B1-L1-[Y] after 4 hours of incubation or (g)
K6B2-L1-[Y] and (h) (H3K)4B1-L1-[Y] after 24 hours of incubation. LPR
complexes were prepared with BODIPY-HPC incorporated into DOTMA/
DOPE lipid (green) and rhodamine labelled Silencers Negative Control
siRNA (red) at a lipid : peptide : siRNA charge ratio of 0.5 : 6 : 1. The cell
nucleus was stained with DAPI (blue). All peptides were unlabelled.
Fig. 10 Confocal microscopy of A549-luc cells transfected with LPR
complexes prepared in 12.5% water then diluted in OptiMEM containing
peptides (a) FITC-K6B2-L1-[Y] and (b) FITC-(H3K)4B1-L1-[Y] after 24 hours
of incubation, or A549-luc cells transfected with LPR complexes prepared
fully in OptiMEM containing peptides (c) FITC-K6B2-L1-[Y] and (d) FITC-
(H3K)4B1-L1-[Y] after 24 hours of incubation. LPR complexes were pre-
pared with FITC-labelled peptides (green, 100%) and rhodamine labelled
Silencers Negative Control siRNA (red) at a lipid : peptide : siRNA charge
ratio of 0.5 : 6 : 1. The cell nucleus was stained with DAPI (blue) and the
lipids were unlabelled.
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With the LPRs formulated from the peptide which showed the
lowest knockdown activity, K6B2-L1-[Y], after 24 hours the peptide
and siRNA are still significantly co-localised (Fig. 10a and c).
In contrast, with the LPRs formulated from the peptide with the
highest knockdown activity, (H3K)4B1-L1-[Y], significant amounts
of siRNA persist in the cytoplasm and are no longer co-localised
with the peptide (Fig. 10b and d).
Discussion
The use of cationic peptide sequences in PR and LPR formulations
for the delivery of siRNA has previously been studied by a number
of groups.6–17 However, each previous study has tended to focus on
one specific type of cationic residues, whereas in this study we
aimed to compare the effects on complex structure and knockdown
efficiency of complexes formed from Lys, Arg, His, D-Arg, and
mixed Lys/His sequences.
Using the cell line studied in this paper, virtually all peptides
gave impressive knockdown results when formulated into LPR
complexes in water and diluted in OptiMEM (Fig. 2(a–c)). Under
these conditions, even peptides lacking a targeting sequence,
or with the cell targeting sequence scrambled, performed well.
However, under physiologically relevant conditions, in which
the LPR formulations were diluted in serum-containing growth
media, major differences in knockdown efficiency resulted
when both peptide sequence and formulation conditions were
varied (Fig. 2(d–f) and Fig. S1, ESI†). Firstly, LPR formulations
prepared in water and diluted in growth media showed uni-
formly poor knockdown efficiencies, whereas certain LPR for-
mulations prepared in OptiMEM and diluted in growth media
retained good knockdown activities. As the main difference
between the composition of OptiMEM and growth media is
the presence of serum, this observation suggests that, although
there was no difference in the knockdown achieved in the absence
of serum, that the ions present in OptiMEM influenced the
structure of the LPRs in a beneficial way with respect to their
interaction with serum.
The formulations which retained the greatest knockdown
activity when prepared in OptiMEM and diluted in growth
media were those prepared using His-rich peptides. Thus
those LPRs containing the Group 1 peptides, H6B1-L1-[Y] and
H6B1-L2-[Y] produced the greatest levels of knockdown, while
those containing peptides possessing His-rich sequences from
the Group 3 peptides gave good to excellent knockdown. The
sequences (KH3)4B1-L1-[Y] and (H3K)4B1-L1-[Y], which were
identified by Mixson13 as being most eﬀective for siRNA delivery,
also performed the best in our study. However, interestingly there
was no major diﬀerence between LPRs formulated from these
peptides, and LPRs formulated from the other His-rich sequences
which were previously identified as being suboptimal for siRNA
delivery.13 These observations suggest that the charge on the
peptide plays an important role in the knockdown eﬃciency of
the complexes in the presence of serum and that the partially
charged histidine peptides were less aﬀected by its presence
than the more highly charged peptides. This point is further
reinforced by the fact that LPRs prepared from the more highly
charged peptides based on Lys or Arg sequences showed
significantly better activities when the non-charged linker,
GAGA, was used instead of RVRRGA (Fig. 2e). In comparison,
in our previous work studying the eﬀectiveness of these peptides
in delivering DNA in LPD complexes, the His-rich sequences
showed very poor transfection eﬃciencies and the RVRRGA linker
was also critical for good transfection.27 The present results
suggest that the cleavage of the peptide by furin within the
endosome is not the crucial step for knockdown, but rather
release of the siRNA from the complex in the cytoplasm is. This
confirms the observations of other groups that the best delivery
vehicles for DNA may not be optimal for siRNA delivery.1–4 It
should also be noted that, whilst the best knockdown efficiencies
in growthmedia were obtained with LR complexes prepared using
L2K (Fig. 2d–f) these complexes also exhibited the lowest cell
viability (Fig. S3, ESI†), whereas the LPRs studied had over 80%
viability compared to controls.
In order to understand more fully the reasons for these
observations, we carried out a series of biophysical studies
comparing the LPR complexes. PicoGreen fluorescence studies,
and gel shift assays in both the absence and presence of serum,
indicated that the majority of the peptides packaged siRNA
in tightly bound complexes, and that the siRNA packaging
eﬃciency of the complexes was not improved by using more
highly branched peptides. However, the LPR complexes which
showed the best knockdown in the presence of serum – the
His-rich Group 3 peptides and the Group 1 peptides H6B1-L1-[Y]
and H6B1-L2-[Y] – showed reduced siRNA complexation and
protection from siRNA degradation. As siRNA must be released
into the cytoplasm in order to exert its knockdown effect, this
in turn suggests that incomplete complexation of the siRNA
and therefore more effective release from the nanocomplex is key
to the greater knockdown efficiencies of these LPR complexes.
We next compared the eﬀects of LPR complex formulation
with the diﬀerent peptides on the structural properties of these
nanocomplexes. Whilst the sizes of the LPR complexes were
all very similar, regardless of the peptide used, LPRs prepared
with the His- or His-rich peptides had a lower surface charge
(Fig. S5, ESI†), probably due to the lower charges on these
peptides at neutral pH. TEM imaging of the LPR complexes
showed them to be small, homogeneous and electron dense
with no internal structure visible. By comparison, some LPD
nanocomplexes formulated with these peptides had ordered
core structures29 again emphasising the key diﬀerences between
DNA and siRNA carriers. CD studies indicated that in contrast
to LPDs, where the conformation of DNA in the complex was
generally found to be diﬀerent to that free in solution,29 the
conformation of siRNA was unaltered when in the form of an
LPR. Furthermore, CD studies showed that the His- and His-rich
peptides, H6B1-L1-[Y] and (H3K)4B1-L1-[Y] exhibited the greatest
change in their spectra when in the form of an LPR while the
peptides, R6B1-L1-[Y] and K6B2-L1-[Y], which were shown by
PicoGreen fluorescence studies and gel shift assays to bind siRNA
to the greatest extent, preserved their spectra. This suggests that
in order to complex the siRNA, the His and His-rich peptides have
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to undergo an amount of structural change, possibly explaining
the greater tendency of the complexes containing these peptides
to dissociate.
For the majority of peptides, including the His-rich peptide,
(H3K)4B1-L1-[Y], SANS studies indicated that the LPRs contained
a lipid bilayer that possessed virtually identical physico-chemical
properties to the bilayer of the parent vesicles from which they
were formed. Similar results were previously found for LPDs
prepared from the same peptides as studied here.29 Interestingly
however, the bilayer present in the LPRs containing K6B2-L1-[Y]
and K6B1-L1-[Y] although of a similar thickness is thought to be
slightly more rigid than in the parent vesicle. It is not known
what eﬀect the slightly more rigid bilayer may have on the
transfection ability of the LPRs. Furthermore, for reasons as yet
unknown, it was not possible to model the SANS data obtained
for LPRs containing H6B1-L1-[Y] and K6B0-L1-[Y] suggesting the
presence of a mixture of aggregates.
What eﬀects do these diﬀerence in complexation eﬃciency,
surface charge and internal structure have on the fate of the
components once the LPR particles have entered the cell?
Confocal studies on LPR particles formulated either in water/
diluted in OptiMEM, or formulated in OptiMEM/diluted in
OptiMEM, were carried out with the lipid, siRNA and peptide
components variously labelled. When using LPRs prepared
with labelled lipid and siRNA, it was clear that in all cases
the lipid had largely dissociated from the LPR complex after
4 hours, regardless of the peptide sequence, and appeared to
be distributed within endosomal compartments. Similarly, the
siRNA is seen to have dissociated from the lipid and is
distributed throughout the cells, rather than remaining in the
endosomal compartment or being traﬃcked to the nucleus. We
have previously shown for LPD complexes that endosomal
release of the components is most likely mediated by the helper
lipid DOPE, with the ‘‘proton sponge’’ eﬀect of the cationic
peptides in the formulations having only a negligible eﬀect.27
However, the most eﬀective LPR formulations, using either
(H3K)4B1-L1-[Y] or H6B1-L1-[Y], showed larger amounts of
siRNA within the cells and that this higher level of siRNA
persisted, at least up to 24 h after incubation (Fig. 9h and
Fig. S8d, ESI†). Further confocal experiments using labelled
H6B1-L1-[Y] supported the observation that siRNA after 24 hours
incubation was in the cytoplasm of the cell and showed that the
siRNA was no longer co-localised with the peptide (Fig. 10b and d).
By contrast, using labelled lipid and siRNA indicated that little
siRNA was observed in cells treated with LPRs formulated using
the peptide with the lowest knockdown activity but the tightest
siRNA binding, K6B1-L1-[Y]. Furthermore, when studying LPRs
formulated using labelled K6B2-L1-[Y] and siRNA showed that the
labelled peptide was significantly co-localised with siRNA after
24 hours (Fig. 10a and c).
Conclusions
We have carried out a comprehensive comparative study of the
siRNA delivery and gene knockdown properties of nanoparticles
formulated from diﬀerent cationic peptide sequences, a 1 : 1
mixture of the lipids DOTMA and DOPE, and siRNA. We have
compared polyplex (PR) and lipopolyplex (LPR) formulations
and have demonstrated that the LPR formulations have signifi-
cantly better gene knockdown under a range of conditions. In
the cell line studied, and in these ternary complexes, branched
peptides containing His or mixed His-Lys sequences are the
most eﬀective, particularly when knockdown experiments are
carried out in physiologically relevant growth media. Furthermore,
these lipopolyplex formulations were much less toxic than those
prepared using the current ‘‘standard’’ reagent, L2K.
In order to understand the molecular basis for these findings,
we have studied the biophysical properties of these nano-
complexes in detail. We have shown that the looser binding
of the mixed His/Lys peptides to their siRNA cargo is key to
their higher knockdown eﬃciencies, and that this is an eﬀect
arising from both lower peptide charge at pH7 and a diﬀerent
geometry of interaction between peptide and siRNA. These
in turn lead to nanoparticles in which the siRNA is more
eﬃciently delivered and persists for longer in the cells. Impor-
tantly, we have also shown that the conditions under which the
LPR complexes are formulated are critical to the knockdown
eﬃciencies in serum, with nanocomplexes formulated in
OptiMEM and subsequently diluted in serum being most eﬀective.
Whilst OptiMEM would not be regarded as a suitable formulation
solvent for clinical studies, where well defined, simple electrolyte
solvents are preferred, these results suggest that formulating LPR
complexes under conditions of higher salt would be beneficial for
delivery of siRNA under physiologically relevant conditions. Further
studies in this area are currently in progress and will be reported in
due course.
Experimental procedures
Materials
The synthesis of the bifunctional peptides used in the present
study has been previously described.29 Characterisation data
for the control (scrambled) peptide sequence, sK6B1-L1-[Y] is
given in the ESI.† The methods used for the FITC labelling of
selected peptides (namely K6B2-L1-[Y] and (H3K)4B1-L1-[Y]) are
detailed in the ESI.† Silencers Firefly Luciferase (GL2 + GL3)
(Luc-siRNA) and Silencers Negative Control siRNA #1 were
purchased from Ambion (USA). A custom-made siRNA sequence,
CUU ACG CUG AGU ACU UCG dTdT, termed here Sigma siRNA
was purchased from Sigma-Aldrich (UK) and used for samples
requiring high amounts of siRNA, namely small angle neutron
scattering (SANS), dynamic light scattering, zeta potential and
circular dichroism (CD) measurements. Uranyl acetate, agarose,
RNAse A, RNAse inhibitor, poly-L-aspartic acid (pAsp) and
all cell culture growth media and other reagents including
1,4-diazabicyclo[2.2.2]octane (DABCO) were purchased from
from Sigma (UK), unless otherwise stated. 40,6-Diamidino-2-
phenylindole dihydrochloride (DAPI) and Pierce BCA Protein
Assay kit were was purchased from Thermo Scientific (UK).
OptiMEM, Lipofectamine 2000 (L2K), PicoGreen reagent and
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2-(4,4-difluoro-5-methyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoyl)-
1-hexadecanoyl-sn-glycero-3-phosphocholine (b-BODIPYs 500/510
C12-HPC) (BODIPY-HPC) were purchased from Invitrogen
Molecular probes, UK. Label-ITs TM-Rhodamine siRNA Tracker
Intracellular Localization Kit was supplied by Mirus (USA).
GelRed nucleic acid stain was obtained from Cambridge Bio-
science (UK). N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium
chloride (DOTMA) was obtained from TCI Europe, Belgium, and
dioleylphosphatidylethanolamine (DOPE) was obtained from Avanti
Polar lipids, Alabama, Alabaster, USA. GelRed was purchased from
Gencompare, Belgiun and Luciferase assay kit was purchased from
Promega (UK). Human alveolar A549-Luc cells, stably transfected
with an episomal S/MAR luciferase vector as described by Argyros
et al.36 were a gift fromDrM. T. Thanou (Institute of Pharmaceutical
Science, King’s College London, UK). All reagents were of the highest
grade possible and were used without further purification. Double
distilled, filtered water was used throughout. D2O (499% purity)
was obtained from Aldrich (UK).
Preparation of liposomes and stock solutions
Cationic lipid vesicles composed of DOTMA :DOPE at 1 : 1
molar ratio were prepared as previously described.29 Briefly a
thin film of lipid, obtained by evaporating chloroform from a
lipidic chloroform solution, was hydrated with suﬃcient filtered,
double distilled water to produce a DOTMA concentration of
1 mg mL1. The resulting crude lipid suspension was then probe
sonicated (using a Lucas Dawes probe sonicator operating at 50%
output for 10 minutes at room temperature) to produce small
unilamellar vesicles ofB60 nm in diameter.
Peptide solution (1 mg mL1), siRNA solution and vesicle
suspensions were diluted, as required, using either double
distilled, filtered water (for dynamic light scattering, zeta
potential, gel shift assays and TEM) or D2O (for CD and SANS),
or in the case of knockdown studies, water or OptiMEM to give
the required siRNA and peptide stock solutions, and the lipid
stock suspensions for the preparation of PR and LPR complexes.
Formation of PR and LPR
Polyplexes (complexes of Peptide and siRNA, PR complexes)
were formulated by adding equal volumes of the required
siRNA stock solution to a peptide solution containing suﬃcient
peptide to produce PRs at either a 6 : 1 or 12 : 1 (nominal)
charge ratio, i.e. assuming all peptides are fully ionised under
the conditions of use. The concentrations used depending on
the nature of the experiment to be performed.
Lipopolyplexes (complexes of Lipid, Peptide and siRNA, LPR
complexes) were prepared at LPR (nominal) charge ratios of
0.5 : 6 : 1 and 0.5 : 12 : 1 (i.e. assuming all peptides are fully
ionised under the conditions of use) by first mixing equal
volumes of cationic vesicles suspension and peptide solution
and then adding with thorough mixing an equal volume of
siRNA solution. For example, for the in vitro cell studies, 75 mL
of a peptide solution (at the required concentration) was added
to 75 mL DOTMA:DOPE vesicle suspension (containing 5.7 mgmL1
of DOTMA). To this lipid:peptide mixture, an equal volume of
siRNA solution (i.e. 150 mL of a 2.7 mg mL1 siRNA solution) was
added and the LPDs prepared by the gentle shaking of the
resulting suspension.
Dynamic light scattering and zeta potential measurements
The apparent hydrodynamic size and the zeta potential of the
LPR and PR complexes weremeasured by dynamic light scattering
at 25  0.1 1C using a Zetasizer Nano ZS (Malvern Instruments,
UK). LPR and PR complexes were prepared in double distilled,
filtered water at L : P :R charge ratios of 0.5 : 6 : 1 and 0.5 : 12 : 1
and P :R charge ratios of 6 : 1 and 12 : 1 using Sigma siRNA (final
siRNA concentration of 26 mg mL1 for the DLS measurements
and 2.9 mg mL1 for the zeta potential measurements). Three
repeat measurements were made for each complex. In all cases
the complexes exhibited polydispersities of less than 0.3.
Circular dichroism spectroscopy
The circular dichroism (CD) and ultra violet (UV) spectra of
siRNA, LPRs and PRs, dispersed in D2O, were measured at
20  2 1C using a Chirascan Plus spectrometer (Applied
Photophysics, UK) operated with a scan speed of 30 nm min1,
a bandwidth of 1 nm and a time per point of 2 s. Spectra were
recorded between 320 and 180 nm using a 1 mm path length
cell. CD and UV absorbance spectra were acquired simulta-
neously. All spectra were corrected for a D2O background,
which was measured periodically throughout the experiment.
The CD and UV spectra of siRNA were measured at a concen-
tration 4 mM (0.050 mg mL1). The spectra of the LPR and PR
complexes were measured at charge ratios of 0.5 : 6 : 1 and 6 : 1,
and a siRNA concentration of 0.050 mg mL1.
Transmission electron microscopy
LPR and PR complexes, prepared at charge ratios of 0.5 : 6 : 1
and 6 : 1, respectively and a final siRNA concentration of 0.05
mg mL1, were examined using transmission electron micro-
scopy (TEM) by negative staining with an aqueous solution of
4% w/v uranyl acetate. Briefly, a drop of sample was placed on a
formvar 200 mesh copper grid for one minute before the excess
liquid was removed using a wick of filter paper. A drop of uranyl
acetate was then added to the grid for approximately five
minutes after which time the grid was washed with an aqueous
solution of 50% v/v ethanol. After drying the samples were visualized
using an FEI TecnaiTM transmission electron microscope (USA).
Small angle neutron scattering
The small angle neutron scattering (SANS) of LPRs and DOTMA:
DOPE vesicles was measured on the SANS2D and LoQ beamlines
at the ISIS pulsed neutron source (ISIS Facility, the Rutherford-
Appleton Laboratories, Didcot, UK). Freshly prepared DOTMA:
DOPE vesicles dispersed in D2O were measured at a DOTMA
concentration of 1 mg mL1. LPR complexes were similarly freshly
prepared in either 8.2 vol% D2O in H2O or D2O at a Sigma siRNA
concentration of 0.1 mg mL1 and a L :P :R charge ratio of
0.5 : 6 : 1. The SANS of the LPRs and vesicles and the relevant
solvents were measured in 2 mm path length circular silica cells at
25  0.1 1C. Where possible, the SANS of the parent vesicles and
the LPRs were measured on more than one occasion to ensure the
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reproducibility of the data. Dynamic light scattering measurements
of the vesicles and LPRs prepared in D2O confirmed that their
preparation did not alter the size of the resulting nanoparticles.
The SANS intensity, I(Q), of the LPDs and vesicles as a function
of the scattering vector, Q = (4p/l)sin(y/2), where y/2 is the
scattering angle, was determined by normalising the scattering
to the appropriate sample transmission after subtraction of
the scattering from the relevant solvent also normalised to its
corresponding transmission. The fitting of the SANS data
always included flat background corrections to allow for any
mismatch in the incoherent and inelastic scattering between
the sample and the solvent, with the levels of the fitted back-
ground being checked to ensure that they were physically
reasonable. The SANS data for the DOTMA:DOPE vesicles and
LPR complexes dispersed in D2O were routinely modelled
either assuming a mixture of (isolated/single) infinite planar
(lamellar) sheets with or without one-dimensional paracrystals
(stacks) to account for the presence in the sample of any
multilamellar vesicles. When modelling the vesicles and LPR
complexes dispersed in D2O as (single) lamellar sheets, the fits
to the SANS data were obtained by the least-squares refinement
of three parameters, namely L, Rs, and the absolute scale factor
(together with the background, as described above), where Rs
is the Lorentz correction factor which provides information
about the extent of rigidity/curvature of the lamellar sheets.
Unless otherwise stated a Rs of 250 Å was used. In this study the
polydispersity on the thickness of the bilayer (s(L)/L) was fixed
at 0.1. When stacks were added to the (single) lamellar sheet
model, the fit to the SANS data was obtained by least-squares
refinement of seven parameters, namely Rs, the mean bilayer
thickness (L), the number of bilayers in the stack (M), their
mean separation or d-spacing (D), the width of the Gaussian
distribution in the plane, (s(D)/D), and the absolute scale
factors for the unilamellar and multilamellar vesicles. In the
present study, s(L)/L was again fixed as 0.1 and s(D)/D at 0.05,
with a Rs of 250 Å was used. In addition, when modeling the
SANS data using a mixed population of sheets and stacks, L,
s(L)/L, and Rs were constrained to be the same for the isolated/
single and stacked lamellae, a not unreasonable assumption.
If no Bragg peak was seen in the SANS data, it was fitted using a
stack with a maximum of 2 bilayers. In such cases the data was
fitted using a higher number of bilayers comprising the stacks
to ensure that it did not improve the quality of the fit obtained.
For all models, the least-squares refinements were performed
using the model-fitting routines provided in the FISH software.
Gel band shift assay
Gel electrophoresis experiments were performed to determine
(a) the extent of siRNA complexation, (b) the dissociation of
siRNA in the presence of pAsp and (c) the extent of siRNA
protection from enzymatic degradation by RNAse A, when the
siRNA was formulated as either an LPR or PR complex – either
at a charge ratio of 0.5 : 6 : 1 and 0.5 : 12 : 1 for the LPRs and a
charge ratios of 6 : 1 and 12 : 1 for the PRs. Complexes were
prepared in a volume of 10 mL and at a siRNA concentration of
0.01 mg mL1 (i.e. 0.1 mg siRNA per well). To determine the
extent of siRNA complexation, LPR or PR complexes were used
without further treatment. For siRNA release studies, 1.25 mL
of a 1 mg mL1 aqueous pAsp solution was added to the
complexes. Experiments to determine the level of siRNA protec-
tion afforded by the complexes from enzymatic degradation
were prepared by adding an aqueous solution of RNAse A
(0.4 mL, 0.1 mg mL1), incubating the resultant mixture for
30 min at 37 1C, then adding an aqueous solution of RNAse
inhibitor (0.4 mL, 30–50 000 U mL1) to stop the enzymatic
reaction. The mixture was further incubated at room tem-
perature for 10 min after which time an aqueous pAsp solution
(1.25 mL, 1 mg mL1) was added to release any protected siRNA.
To all prepared samples, 2 mL of gel loading buffer (0.25% w/v
bromphenol blue and 40% w/v sucrose) was added prior to
loading the samples onto a 2% w/v agarose gel in Tris/Borate/
EDTA (TBE) buffer containing 3 mL of GelRed nucleic acid stain
at 80 V for 45 min (Fisher Brand, Model HU12 electrophoreses
chamber) and visualized under UV light using an Alphalmage
EP MultiImage Light Cabinet (Alpha Innotech, South Africa).
Eﬀect of media on lipopolyplex complexation and stability
Gel electrophoresis experiments were also used to determine
the extent of siRNA complexation and stability in LPR complexes
when prepared in diﬀerent conditions. LPRs were prepared in a
total volume of 10 mL at charge ratios of 0.5 : 6 : 1 and a siRNA
concentration of 0.01 mg mL1 using the peptides (K6B1-L1-[Y],
R6B1-L1-[Y], H6B1-L1-[Y], K12B0-L1-[Y], K6B2-L1-[Y] and
(H3K)4B1-L1-[Y]), either fully in water, OptiMEM, or in serum-
containing growth media. LPR complexes were also prepared
initially in water (in 12.5% of the total volume) then diluted
with OptiMEM, serum-containing growth media or 10% fetal
bovine serum (FBS) in water. Free siRNA and complexes of
L2K:siRNA prepared at a 5 : 1 weight ratio in diﬀerent media
conditions and 10 mL of the media alone in the absence of
samples were used as controls. After incubation of all the
samples at 37 1C for 60 minutes, 2 mL of loading buﬀer was
added to each sample before being loaded onto the gel and
visualised as described above.
PicoGreen fluorescence experiments
PicoGreen assays were performed in black 96-well plates. For
each well, 50 mL of PicoGreen reagent (1 : 150 v/v diluted
with Tris-EDTA (TE) buﬀer, pH 7.4) was mixed with 50 mL of
4 mg mL1 of negative control siRNA in TE buﬀer (giving a final
siRNA content of 0.2 mg per well). LPR complexes were then
formulated by adding 100 mL of the siRNA : PicoGreen mixture
to a mixture of equal volumes (25 mL each) of the appropriate
concentration of lipid and peptide. The final LPR ratios were
prepared such that the lipid : siRNA ratio remained constant
at 0.5 : 1, but the peptide : siRNA charge ratio was increased
(to 18 : 1). Fluorescence was measured at lex/lem = 480/520 nm
using a Varian Cary Eclipse fluorescence plate spectrophoto-
meter. In each experiment, naked negative control siRNA mixed
with PicoGreen was regarded as 100% fluorescence and was used
to normalize the PicoGreen signal detected from the complexes.
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Cell culture
A549-Luc cells were maintained in RPMI-1640 growth medium
supplemented with 10% v/v fetal bovine serum (FBS), 1% v/v
of 100 strength non-essential amino acids (NEAA), 1% v/v
penicillin/streptomycin solution (10 000 U mL1/10 mg mL1)
and 1% v/v L-glutamine 200 mM. All cells were maintained at
37 1C, 5% CO2 and 90% relative humidity. The cells were
passaged every three to four days when around 70% confluent
using 0.25% w/v trypsin–EDTA solution.
In vitro knockdown experiments
L2K was used in all knockdown experiments as a positive
control when mixed with siRNA at a L2K:siRNA weight ratio
of 5 : 1. Free Luc-siRNA was used as a negative control. A549-Luc
cells were seeded onto 96-well plates at 1.2  104 cells per well
and incubated for 24 h at 37 1C in a 5% CO2 and 90% relative
humidity.
The growth medium (100 mL) in each well was then replaced
with 50 mL of either OptiMEM or fresh (serum-containing)
growth medium followed by the addition of 50 mL of the
appropriate LPR complex at a charge ratio of either 0.5 : 6 : 1
or 0.5 : 12 : 1 or a PR complex at a charge ratio of 6 : 1. The eﬀect
of the ionic strength of the solvent used to prepare the com-
plexes and the presence of serum on the knockdown eﬃciency
was tested. For these studies, complexes were either formulated
in water and then diluted 1 volume in 4 in OptiMEM or serum-
containing growth medium, or prepared in OptiMEM and
diluted 1 volume in 4 in OptiMEM or serum-containing growth
media before adding to the cells, which brought the final water
or OptiMEM content to 12.5% v/v. All complexes were tested at
least in quadruplicates but generally sextuplicates. The final
concentration of siRNA in the 100 mL in each well was 50 nM.
Preliminary experiments using LRs prepared using L2K and
LPRs made with K4B1-L1-[Y] were performed at siRNA concen-
trations of 10, 30, 50 and 100 nM in 100 mL per well to
determine the optimal siRNA concentration (Fig. S11, ESI†).
In the case of L2K:siRNA complexes prepared at a lipid : siRA
weight ratio of 5 : 1, knockdown eﬃciency increased with
increasing siRNA concentration up to 50 nM whereafter an
increase in concentration resulted in a levelling oﬀ of knockdown,
while cell toxicity (indirectly measured using a protein assay)
increased with siRNA concentration, being greatest at 100 nM
siRNA. When studying LPRs prepared using K4B1-L1-[Y] at a
charge ratio of 0.5 : 12 : 1, a progressive increase in knockdown
eﬃciency was observed upon increasing siRNA dose, however
some toxicity was also observed at 100 nM siRNA. For these
reasons, 50 nM of siRNA in 100 mL per well was used in all
subsequent knockdown experiments.
Knockdown experiments were carried out at LPR ratios
of 0.5 : 6 : 1 and 0.5 : 12 : 1, in line with previous studies.29,37
Peptide : siRNA (PR) complexes were also tested for selected
peptides at 6 : 1 charge ratio (Fig. S2, ESI†).
Complexes were added to the cells and incubated for 24 h at
37 1C. The supernatant was removed and replaced by growth
medium and incubated for a further 24 h. Each complex was
formulated and tested using Luc-siRNA as well as the negative
control siRNA and all knockdown results were expressed as %
knockdown eﬃciency compared to the luciferase expression
produced by the same formulation prepared using the negative
control siRNA. A linear relationship between luminescence and
protein cell content was measured at protein concentrations of
up to B0.018 mg of protein per well (Fig. S12, ESI†). The
protein content in all subsequent knockdown experiments
was therefore monitored to ensure that it fell within the linear
region of the luminescence graph.
Luciferase activity, analyzed 48 h after addition of the
complexes, was determined in cell lysates using a commercial
luciferase assay according to the manufacturer’s protocol.
Briefly, cells were rinsed with 50 mL phosphate buﬀered saline
(PBS) then lysed by the incubation of 50 mL of 1 x Reporter Lysis
Buﬀer (provided in the luciferase assay kit) for 1 h at 25 1C.
After freezing the cells for 30 min at 80 1C, the lysed cells were
thawed and 30 mL of the lysate transferred to a white 96-well
plate. The luciferase activity was then measured over 10 s using
a MLX Microtitres Plate Luminometer (Dynex Technologies,
USA) after delivering 100 mL of the reconstituted Luciferase
assay reagent into each well through an automated feeding
system.
The amount of protein in each cell lysate was determined
using a Pierce BCA Protein Assay kit according to manufacture’s
instructions. Briefly, the cell lysate (20 mL) and bovine serum
albumin (BSA) protein standards (20 mL) were transferred into
a transparent 96 well plate to which mix reagent A/B (200 mL,
provided in the kit) was added. The plate was incubated with
slight shaking at 37 1C for 30min after which time the absorbance
was measured at 562 nm using a SpectraMax 190 plate reader
(Molecular Device, USA). All luciferase measurements were
normalised against the protein content of each well. Knock-
down experiments were repeated on at least two diﬀerent
occasions to confirm that the results were reproducible (results
of only one experiment reported).
Confocal fluorescence internalisation studies
A549-luc cells (1.2  105 cells per well) were incubated with LPR
complexes in 24-well plates fitted with sterilized 13 mm circular
cover slips (Agar Scientific, UK) as described above with the
exception of using fluorescently labelled lipid (10% of lipid
replaced with BODIPY-HPC (green)) and siRNA labelled
with TM-Rhodamine (red) using a Label-ITs TM-Rhodamine
siRNA Tracker Intracellular Localization Kit according to the
manufacturer’s protocol. In addition LPRs were also made
using FITC labelled peptides, either FITC-K6B2-L1-[Y] or FTIC-
(H3K)4B1-L1-[Y] (green, 100%) and TM-Rhodamine (red) labelled
siRNA and (unlabelled) lipid. The total volume in each well was
400 mL, with a siRNA concentration of 50 nM.
After incubation for 4 h or 24 h, the complexes were removed
and the cells washed once with PBS before fixation of the cells
with 4% w/v paraformaldehyde in PBS for 20 min, and permea-
bilization using 0.2% v/v Triton X-100 solution for 20 min
followed by treatment with 1 mg mL1 of sodium borohydride
in PBS for 5 min. The cell nucleus was stained blue by the
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addition of an aqueous DAPI solution (1 mg mL1) for 1 min.
The cover slips were washed with PBS several times and mounted
onto microscope slides using Mowiol 4-88 mounting media
containing 2.5% w/v DABCO. Confocal fluorescence images were
acquired on a Leica DMIRE2 confocal fluorescence laser-scanning
microscope (Leica Microsystems, Germany).
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